Enlivex Therapeutics (NASDAQ:ENLV) Stock Price Up 6% – Still a Buy?

Enlivex Therapeutics Ltd. (NASDAQ:ENLV)’s stock price was up 6% during mid-day trading on Thursday . The stock traded as high as $1.25 and last traded at $1.24. Approximately 94,208 shares were traded during mid-day trading, a decline of 35% from the average daily volume of 145,177 shares. The stock had previously closed at $1.17.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price target on shares of Enlivex Therapeutics in a report on Friday, September 27th. D. Boral Capital reaffirmed a “buy” rating and set a $13.00 target price on shares of Enlivex Therapeutics in a report on Wednesday, December 11th.

Enlivex Therapeutics Price Performance

The firm’s 50-day simple moving average is $1.21 and its 200 day simple moving average is $1.33. The firm has a market capitalization of $26.54 million, a price-to-earnings ratio of -1.27 and a beta of 1.01.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. XTX Topco Ltd acquired a new position in Enlivex Therapeutics during the 2nd quarter worth approximately $35,000. Sigma Investment Counselors Inc. bought a new stake in shares of Enlivex Therapeutics during the third quarter worth $50,000. Finally, Armistice Capital LLC acquired a new position in shares of Enlivex Therapeutics during the second quarter worth $2,415,000. Institutional investors own 1.02% of the company’s stock.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.